Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

被引：36

作者：

Goldschmidt, H

Sonneveld, P

Cremer, FW

van der Holt, B

Westveer, P

Breitkreutz, I

Benner, A

Glasmacher, A

Schmidt-Wolf, IGD

Martin, H

Hoelzer, D

Ho, AD

Lokhorst, HM

机构：

[1] Univ Heidelberg, Med Klin & Poliklin 5, D-69115 Heidelberg, Germany

[2] Univ Rotterdam Hosp, Dept Hematol, NL-3015 GD Rotterdam, Netherlands

[3] Univ Rotterdam Hosp, HOVON Data Ctr, NL-3015 GD Rotterdam, Netherlands

[4] Deutsch Krebsforschungszentrum, Zent Einheit Biostat, D-69120 Heidelberg, Germany

[5] Univ Bonn, Med Klin & Poliklin 1, D-53105 Bonn, Germany

[6] Univ Klin Frankfurt, Med Klin 3, D-60596 Frankfurt, Germany

[7] Univ Utrecht Hosp, Dept Hematol, NL-3584 CX Utrecht, Netherlands

来源：

关键词：

D O I：

10.1007/s00277-003-0685-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：654 / 659

页数：6